Roh-Eul Yoo1,2, Tae Jin Yun3,4, Inpyeong Hwang1,2, Eun Kyoung Hong1,2, Koung Mi Kang1,2, Seung Hong Choi1,2, Chul-Kee Park5, Jae-Kyung Won6, Ji-Hoon Kim1,2, Chul-Ho Sohn1,2. 1. Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea. 2. Department of Radiology, Seoul National University Hospital, 101, Daehangno, Jongno-gu, Seoul, 110-744, Republic of Korea. 3. Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea. radiologyyun@gmail.com. 4. Department of Radiology, Seoul National University Hospital, 101, Daehangno, Jongno-gu, Seoul, 110-744, Republic of Korea. radiologyyun@gmail.com. 5. Department of Neurosurgery, Seoul National University Hospital, Seoul, Republic of Korea. 6. Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
Abstract
OBJECTIVES: Prediction of progression-free survival (PFS) and overall survival (OS) and early identification of molecular biomarkers with prognostic information are clinically important in glioblastoma (GBM) patients. We aimed to explore the utility of arterial spin labeling perfusion-weighted imaging (ASL-PWI) in the prediction of molecular biomarkers and survival in GBM patients. METHODS: We retrospectively analyzed 149 consecutive GBM patients, who had undergone maximal surgical resection or biopsy followed by concurrent chemoradiotherapy and adjuvant chemotherapy using temozolomide between November 2010 and June 2016. On preoperative ASL-PWI, cerebral blood flow (CBF) within contrast-enhancing (CE) and nonenhancing (NE) portions were evaluated both qualitatively (perfusion pattern[CE] and perfusion pattern[NE]) and quantitatively (nCBFCE and nCBFNE). ASL-PWI findings were correlated with molecular biomarkers, including isocitrate dehydrogenase (IDH) and O6-methylguanine-DNA methyltransferase (MGMT) methylation statuses, and survival, using the Mann-Whitney U-test, Spearman rank correlation, Kaplan-Meier analysis, and receiver operating characteristics analysis. RESULTS: nCBFCE was significantly higher in the IDH wild-type group than in the IDH mutant group (p = .013) and in the MGMT unmethylated group than in the methylated group (p = .047). Areas under the receiver operating characteristic curve were 0.678 for IDH mutation (p = .022) and 0.601 for MGMT promoter methylation (p = .043). Hyperperfusion was associated with the shortest median PFS for both perfusion pattern[CE] (7.6 months) and perfusion pattern[NE] (4.0 months). The perfusion pattern[NE] remained an independent predictor for PFS and OS even after adjusting for clinical and molecular predictors, unlike perfusion pattern[CE]. CONCLUSIONS: ASL-PWI can aid to predict survival and molecular biomarkers including IDH mutation and MGMT promoter methylation statuses in GBM patients. KEY POINTS: • ASL-PWI can aid to predict survival in GBM patients. • ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM.
OBJECTIVES: Prediction of progression-free survival (PFS) and overall survival (OS) and early identification of molecular biomarkers with prognostic information are clinically important in glioblastoma (GBM) patients. We aimed to explore the utility of arterial spin labeling perfusion-weighted imaging (ASL-PWI) in the prediction of molecular biomarkers and survival in GBM patients. METHODS: We retrospectively analyzed 149 consecutive GBM patients, who had undergone maximal surgical resection or biopsy followed by concurrent chemoradiotherapy and adjuvant chemotherapy using temozolomide between November 2010 and June 2016. On preoperative ASL-PWI, cerebral blood flow (CBF) within contrast-enhancing (CE) and nonenhancing (NE) portions were evaluated both qualitatively (perfusion pattern[CE] and perfusion pattern[NE]) and quantitatively (nCBFCE and nCBFNE). ASL-PWI findings were correlated with molecular biomarkers, including isocitrate dehydrogenase (IDH) and O6-methylguanine-DNA methyltransferase (MGMT) methylation statuses, and survival, using the Mann-Whitney U-test, Spearman rank correlation, Kaplan-Meier analysis, and receiver operating characteristics analysis. RESULTS: nCBFCE was significantly higher in the IDH wild-type group than in the IDH mutant group (p = .013) and in the MGMT unmethylated group than in the methylated group (p = .047). Areas under the receiver operating characteristic curve were 0.678 for IDH mutation (p = .022) and 0.601 for MGMT promoter methylation (p = .043). Hyperperfusion was associated with the shortest median PFS for both perfusion pattern[CE] (7.6 months) and perfusion pattern[NE] (4.0 months). The perfusion pattern[NE] remained an independent predictor for PFS and OS even after adjusting for clinical and molecular predictors, unlike perfusion pattern[CE]. CONCLUSIONS: ASL-PWI can aid to predict survival and molecular biomarkers including IDH mutation and MGMT promoter methylation statuses in GBM patients. KEY POINTS: • ASL-PWI can aid to predict survival in GBM patients. • ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM.
Authors: Wolfgang Wick; Roger Stupp; Anna-Carina Beule; Jacoline Bromberg; Antje Wick; Ulrike Ernemann; Michael Platten; Christine Marosi; Warren P Mason; Martin van den Bent; Michael Weller; Chris Rorden; Hans-Otto Karnath Journal: Neuro Oncol Date: 2008-07-31 Impact factor: 12.300
Authors: Veronique Frattini; Vladimir Trifonov; Joseph Minhow Chan; Angelica Castano; Marie Lia; Francesco Abate; Stephen T Keir; Alan X Ji; Pietro Zoppoli; Francesco Niola; Carla Danussi; Igor Dolgalev; Paola Porrati; Serena Pellegatta; Adriana Heguy; Gaurav Gupta; David J Pisapia; Peter Canoll; Jeffrey N Bruce; Roger E McLendon; Hai Yan; Ken Aldape; Gaetano Finocchiaro; Tom Mikkelsen; Gilbert G Privé; Darell D Bigner; Anna Lasorella; Raul Rabadan; Antonio Iavarone Journal: Nat Genet Date: 2013-08-05 Impact factor: 38.330
Authors: Philipp Kickingereder; Felix Sahm; Alexander Radbruch; Wolfgang Wick; Sabine Heiland; Andreas von Deimling; Martin Bendszus; Benedikt Wiestler Journal: Sci Rep Date: 2015-11-05 Impact factor: 4.379
Authors: Dieter Henrik Heiland; Theo Demerath; Elias Kellner; Valerij G Kiselev; Dietmar Pfeifer; Oliver Schnell; Ori Staszewski; Horst Urbach; Astrid Weyerbrock; Irina Mader Journal: Oncotarget Date: 2017-02-14
Authors: Tineke van de Weijer; Martijn P G Broen; Rik P M Moonen; Ann Hoeben; Monique Anten; Koos Hovinga; Inge Compter; Jochem A J van der Pol; Cristina Mitea; Toine M Lodewick; Arnaud Jacquerie; Felix M Mottaghy; Joachim E Wildberger; Alida A Postma Journal: Diagnostics (Basel) Date: 2022-05-11
Authors: Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain Journal: J Neurooncol Date: 2021-03-04 Impact factor: 4.130
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639
Authors: Elies Fuster-Garcia; David Lorente Estellés; María Del Mar Álvarez-Torres; Javier Juan-Albarracín; Eduard Chelebian; Alex Rovira; Cristina Auger Acosta; Jose Pineda; Laura Oleaga; Enrique Mollá-Olmos; Silvano Filice; Paulina Due-Tønnessen; Torstein R Meling; Kyrre E Emblem; Juan M García-Gómez Journal: Eur Radiol Date: 2020-10-01 Impact factor: 5.315